image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
8972e89bad9919ad83c32b48e7b9e9cd51e4789b2ccabb477e312941d5761c82.png | simple | <table><tr><td>Parameters</td><td>School A</td><td>School B</td></tr><tr><td><i>q</i><sub><i>c</i></sub>, mean [ 95 <i>%</i> CI]</td><td>1.39×10<sup>−2</sup> [ 8.10×10<sup>−3</sup>−2.03×10<sup>−2</sup>]</td><td>1.96×10<sup>−2</sup> [ 1.11×10<sup>−2</sup>ͨ... | <table><tr><td>Parameters</td><td>School A</td><td>School B</td></tr><tr><td>qc, mean [ 95 % CI]</td><td>1.39×10−2 [ 8.10×10−3−2.03×10−2]</td><td>1.96×10−2 [ 1.11×10−2−2.89×10−2]</td></tr><tr><td>qg, mean [ 95 % CI]</td><td>4.36×10−3 [ 9.61×10−4−8.34×10−3]</td><td>4.61×10−3 [ 2.98×10−4−1.15×10−2]</td></tr></table> | <table><tr><td>qs, mean [ 95 % CI]</td><td>9.52×10−4 [ 2.87×10−4−1.82×10−3]</td><td>2.96×10−3 [ 1.64×10−3−4.45×10−3]</td></tr><tr><td>ε, mean [ 95 % CI]</td><td>3.70×10−3 [ 1.95×10−3−5.69×10−3]</td><td>2.65×10−3 [ 1.37×10−3−4.20×10−3]</td></tr></table> |
6c338e811af9402b98f215c9759761bc6c3def789a9ad83789f208d267d0006a.png | complex | <table><tr><td>Dependent variable</td><td colspan="2">ANC4</td><td colspan="2">SBA</td><td colspan="2">IFD</td></tr><tr><td>Density variable</td><td>% "urban"</td><td>score</td><td>% "urban"</td><td>score</td><td>% "urban"</td><td>score</td></tr><tr><td rowspan="2">Density</td><td>0.003***</td><td>0.002**</td><td>0.004... | <table><tr><td>Dependent variable</td><td colspan="2">ANC4</td><td colspan="2">SBA</td><td colspan="2">IFD</td></tr><tr><td>Density variable</td><td>% "urban"</td><td>score</td><td>% "urban"</td><td>score</td><td>% "urban"</td><td>score</td></tr><tr><td rowspan="2">Density</td><td>0.003***</td><td>0.002**</td><td>0.004... | <table><tr><td>Dependent variable</td><td colspan="2">ANC4</td><td colspan="2">SBA</td><td colspan="2">IFD</td></tr><tr><td>Density variable</td><td>% "urban"</td><td>score</td><td>% "urban"</td><td>score</td><td>% "urban"</td><td>score</td></tr><tr><td rowspan="2"># 4-wheel vehicles, per capita</td><td>0.035</td><td>0... |
8be7af498b313fcdc872c170f32425cebc75098e7c2119ea1b47a88c691245eb.png | complex | <table><tr><td></td><td>Weeks</td><td>Daily dose</td><td>Niaspan FCT dosage</td></tr><tr><td rowspan="4">Initial titration schedule</td><td>0 to 4</td><td>500 mg</td><td>One 500 mg tablet at bedtime</td></tr><tr><td>5 to 8</td><td>1,000 mg</td><td>One 1,000 mg tablet or two 500 mg tablets at bedtime</td></tr><tr><td>9 ... | <table><tr><td></td><td>Weeks</td><td>Daily dose</td><td>Niaspan FCT dosage</td></tr><tr><td rowspan="3">Initial titration schedule</td><td>0 to 4</td><td>500 mg</td><td>One 500 mg tablet at bedtime</td></tr><tr><td>5 to 8</td><td>1,000 mg</td><td>One 1,000 mg tablet or two 500 mg tablets at bedtime</td></tr><tr><td>9 ... | <table><tr><td></td><td>Weeks</td><td>Daily dose</td><td>Niaspan FCT dosage</td></tr><tr><td>Initial titration schedule</td><td>13 to 24</td><td>2,000 mg</td><td>Two 1,000 mg tablets at bedtime</td></tr></table> |
60f7079ba6d811dea21e96d519da45548135509ecd489525770ce40514ffb5a0.png | simple | <table><tr><td>Combination</td><td>TP</td><td>FP</td><td>TN</td><td>FN</td><td>sensitivity (HCC = 50)</td><td>specificity (LC = 41)</td><td>TPP</td><td>TPN</td><td>LR</td></tr><tr><td>afp</td><td>28</td><td>0</td><td>41</td><td>22</td><td>56.00%</td><td>100.00%</td><td>100.0%</td><td>65.10%</td><td>-</td></tr><tr><td>a... | <table><tr><td>Combination</td><td>TP</td><td>FP</td><td>TN</td><td>FN</td><td>sensitivity (HCC = 50)</td><td>specificity (LC = 41)</td><td>TPP</td><td>TPN</td></tr><tr><td>afp</td><td>28</td><td>0</td><td>41</td><td>22</td><td>56.00%</td><td>100.00%</td><td>100.0%</td><td>65.10%</td></tr><tr><td>afp+piv</td><td>47</td... | <table><tr><td>LR</td></tr><tr><td>-</td></tr><tr><td>4.82</td></tr><tr><td>4</td></tr><tr><td>2.68</td></tr><tr><td>2.31</td></tr><tr><td>2.15</td></tr><tr><td>1.85</td></tr><tr><td>1.53</td></tr><tr><td>1.46</td></tr><tr><td>1.4</td></tr><tr><td>1.27</td></tr><tr><td>1.27</td></tr><tr><td>1.24</td></tr><tr><td>1.05</... |
da8512c3da0b345d6c822eda63edeec3e5bd7bbf92e06c067178beb54447138f.png | complex | <table><tr><td></td><td>Variable</td><td>OR<sup>a</sup> (IC95%)</td><td><i>p</i><sup>a</sup> value</td><td>OR<sup>B</sup> (IC95%)</td><td><i>p</i><sup>b</sup> value</td></tr><tr><td>PSVI</td><td colspan="5">Part 1</td></tr><tr><td></td><td>Low PSVI</td><td>1</td><td>< 0.01</td><td></td><td></td></tr><tr><td></td><td... | <table><tr><td></td><td>Variable</td><td>ORa (IC95%)</td><td>pa value</td><td>ORB (IC95%)</td><td>pb value</td></tr><tr><td>PSVI</td><td colspan="5">Part 1</td></tr><tr><td></td><td>Low PSVI</td><td>1</td><td>< 0.01</td><td></td><td></td></tr><tr><td></td><td>Middle PSVI</td><td>1.21 (1.21; 1.21)</td><td>< 0.01</td><td... | <table><tr><td></td><td>Variable</td><td>ORa (IC95%)</td><td>pa value</td><td>ORB (IC95%)</td><td>pb value</td></tr><tr><td>Age group</td><td>15–19</td><td>1.09 (1.09; 109)</td><td>< 0.01</td><td>1.04 (1, 1.08)</td><td></td></tr><tr><td></td><td colspan="5">Part 3</td></tr><tr><td>Family income</td><td colspan="5">Hous... |
c26a54401dc062f7ff2aff801c23eccf6a5c71206acd06bc029182e31ca1f01d.png | simple | <table><tr><td> </td><td>Group I(<i>n</i> = 25)</td><td>Group P(<i>n</i> = 25)</td><td><i>P</i> value</td></tr><tr><td>Desaturation (SpO<sub>2</sub> < 90%)</td><td>3 (12%)</td><td>2 (8%)</td><td>1.000</td></tr><tr><td>Gastric insufflations</td><td>1 (4%)</td><td>0 (0%)</td><td>1.000</td></tr><tr><td>Aspiration</td><... | <table><tr><td></td><td>Group I(n = 25)</td><td>Group P(n = 25)</td><td>P value</td></tr><tr><td>Desaturation (SpO2 < 90%)</td><td>3 (12%)</td><td>2 (8%)</td><td>1.000</td></tr><tr><td>Gastric insufflations</td><td>1 (4%)</td><td>0 (0%)</td><td>1.000</td></tr><tr><td>Aspiration</td><td>0 (0%)</td><td>0 (0%)</td><td>—</... | <table><tr><td></td><td>Group I(n = 25)</td><td>Group P(n = 25)</td><td>P value</td></tr><tr><td>Bronchospasm</td><td>0 (0%)</td><td>0 (0%)</td><td>—</td></tr><tr><td>Blood stain</td><td>0 (0%)</td><td>2 (8%)</td><td>0.490</td></tr></table> |
3df4c15b6e133af47b8de862f86279470a08b80f5332c42d7772054da865abf1.png | simple | <table><tr><td>Remaining per-base coverage after B-tail removal</td><td>Number of positions with this coverage in the ZR reference (Bv-95nt data)</td><td>Number of positions with this coverage in the PhiX reference (PhiX-95nt data)</td></tr><tr><td>90 to 100%</td><td>41,130 (40.26%)</td><td>4,016 (91.65%)</td></tr><tr>... | <table><tr><td>Remaining per-base coverage after B-tail removal</td><td>Number of positions with this coverage in the ZR reference (Bv-95nt data)</td></tr><tr><td>90 to 100%</td><td>41,130 (40.26%)</td></tr><tr><td>80 to 90%</td><td>4,056 (3.97%)</td></tr><tr><td>60 to 80%</td><td>1,711 (1.67%)</td></tr><tr><td>40 to 6... | <table><tr><td>Number of positions with this coverage in the PhiX reference (PhiX-95nt data)</td></tr><tr><td>4,016 (91.65%)</td></tr><tr><td>266 (6.07%)</td></tr><tr><td>100 (2.28%)</td></tr><tr><td>0 (0.00%)</td></tr><tr><td>0 (0.00%)</td></tr><tr><td>0 (0.00%)</td></tr></table> |
f8e5e3067d00554e8de86b5f0fc0fd401ea4aa43d2cafca8f83aeb2b3c94593a.png | complex | <table><tr><td rowspan="3">Parameter</td><td rowspan="3">DF</td><td rowspan="2" colspan="2">TPC</td><td colspan="6">Antioxidant Capacity</td></tr><tr><td colspan="2">ABTS</td><td colspan="2">DPPH</td><td colspan="2">CUPRAC</td></tr><tr><td><i>F</i></td><td><i>p</i> > <i>F</i></td><td><i>F</i></td><td><i>p</i> > <... | <table><tr><td rowspan="3">Parameter</td><td rowspan="3">DF</td><td rowspan="2" colspan="2">TPC</td><td colspan="6">Antioxidant Capacity</td></tr><tr><td colspan="2">ABTS</td><td colspan="2">DPPH</td><td colspan="2">CUPRAC</td></tr><tr><td>F</td><td>p > F</td><td>F</td><td>p > F</td><td>F</td><td>p > F</td><td>F</td><t... | <table><tr><td>23</td><td>1</td><td>2</td><td>0</td><td>1</td><td>60</td><td>0.86</td><td>0.40</td><td>6</td><td>3</td></tr><tr><td>β11</td><td>1</td><td>6.65</td><td>0.05 *</td><td>7.59</td><td>0.04 *</td><td>0.85</td><td>0.40</td><td>7.26</td><td>0.04*</td></tr><tr><td>β22</td><td>1</td><td>0.11</td><td>0.75</td><td>... |
903042a25ca43bbf9921d7abf1757d3c6c75af5fb987812cb41cdb01eb670685.png | simple | <table><tr><td>Medical categories</td><td>Number of species</td><td>Citations</td><td>Fic</td></tr><tr><td>Tonic</td><td>5</td><td>38</td><td>0.89</td></tr><tr><td>Dermatological</td><td>4</td><td>120</td><td>0.97</td></tr><tr><td>Gastrointestinal</td><td>32</td><td>433</td><td>0.92</td></tr><tr><td>Galactagogue</td><t... | <table><tr><td>Medical categories</td><td>Number of species</td><td>Citations</td></tr><tr><td>Tonic</td><td>5</td><td>38</td></tr><tr><td>Dermatological</td><td>4</td><td>120</td></tr><tr><td>Gastrointestinal</td><td>32</td><td>433</td></tr><tr><td>Galactagogue</td><td>8</td><td>86</td></tr><tr><td>Reproductive</td><t... | <table><tr><td>Fic</td></tr><tr><td>0.89</td></tr><tr><td>0.97</td></tr><tr><td>0.92</td></tr><tr><td>0.91</td></tr><tr><td>0.93</td></tr><tr><td>0.89</td></tr><tr><td>0.91</td></tr><tr><td>0.90</td></tr><tr><td>0.85</td></tr></table> |
70bf8d7bdd26521240c6df2c0310cd7ece22e69d598f725caf8d4247d3790079.png | simple | <table><tr><td>Marker</td><td>Peripheral stroma</td><td>Central stroma</td><td>Anterior stroma</td><td>Posterior stroma</td></tr><tr><td>ABCG2</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>ABCG5</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>ALDH1A1</... | <table><tr><td>Marker</td><td>Peripheral stroma</td><td>Central stroma</td><td>Anterior stroma</td><td>Posterior stroma</td></tr><tr><td>ABCG2</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>ABCG5</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>ALDH1A1</td><td>++</td><td>++</td><td>++</td><td>+</td></... | <table><tr><td>Fibroblast marker</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Fibronectin</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Ki-67</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>Nestin</td><td>−</td><td>−</td><td>−</td><td>−</td></tr><tr><td>VE-Cadherin</td><td>−</td><td>−</t... |
18e1b93b8340cf2b853cddc614226757d23d6bdeeef0a3e94530be06efbe04b2.png | complex | <table><tr><td></td><td colspan="4">Ezetimibe plus Fenofibrate</td><td colspan="4">Atorvastatin Monotherapy</td><td></td><td></td></tr><tr><td></td><td>Baseline</td><td>6 Weeks</td><td>% Change</td><td>p Value</td><td>Baseline</td><td>6 Weeks</td><td>% Change</td><td>p Value</td><td>% Difference</td><td>p Value</td></t... | <table><tr><td></td><td colspan="4">Ezetimibe plus Fenofibrate</td><td>Atorvastatin Monotherapy</td></tr><tr><td></td><td>Baseline</td><td>6 Weeks</td><td>% Change</td><td>p Value</td><td>Baseline</td></tr><tr><td>Total Chol (mmol/L)</td><td>5.9</td><td>4.4</td><td>-25.1</td><td>< 0.001</td><td>5.8</td></tr><tr><td>LDL... | <table><tr><td colspan="3">Atorvastatin Monotherapy</td><td></td><td></td></tr><tr><td>6 Weeks</td><td>% Change</td><td>p Value</td><td>% Difference</td><td>p Value</td></tr><tr><td>4.4</td><td>-24.6</td><td>< 0.001</td><td>-0.4</td><td>0.806</td></tr><tr><td>2.3</td><td>-36.7</td><td>< 0.001</td><td>2.1</td><td>0.46</... |
42597d9582fe42683d4bcea786ddf46f1cfbd60f5714f6206a665bd779c02c8f.png | complex | <table><tr><td rowspan="3">Axis</td><td colspan="2">CoG Position</td><td colspan="2">Linear Acceleration</td></tr><tr><td>First Version</td><td>Second Version</td><td>First Version</td><td>Second Version</td></tr><tr><td><i>X</i></td><td>2.4252e−06</td><td>1.0008e−06</td><td>--*</td><td>--*</td></tr><tr><td... | <table><tr><td rowspan="3">Axi</td><td colspan="2">CoG Position</td><td colspan="2">Linear Acceleration</td></tr><tr><td>First Version</td><td>Second Version</td><td>First Version</td><td>Second Version</td></tr><tr><td colspan="4"></td></tr></table> | <table><tr><td>s</td><td colspan="4"></td></tr><tr><td>X</td><td>2.4252e−06</td><td>1.0008e−06</td><td>--*</td><td>--*</td></tr><tr><td>Y</td><td>1.3992e−05</td><td>1.3390e−05</td><td>6.3191e−06</td><td>5.1146e−06</td></tr><tr><td>Z</td><td>1.5306e−05</td><td>4.4980e−06</td><td>2.7849e−06</td><td>2.3104e−06</td></tr></... |
834c2f9603f4bacecdf442d509f5486e5987a4f4604b79241771b8f8c29329cd.png | simple | <table><tr><td></td><td>Over-expressed in melan-a v B16</td><td>Under-expressed in melan-a v B16</td><td>Total</td></tr><tr><td>Upregulated by RA treatment</td><td>71</td><td>14</td><td>85</td></tr><tr><td>Downregulated by RA treatment</td><td>16</td><td>132</td><td>151</td></tr><tr><td>Total</td><td>87</td><td>149</td... | <table><tr><td></td><td>Over-expressed in melan-a v B16</td><td>Under-expressed in melan-a v B16</td><td>Total</td></tr></table> | <table><tr><td>Upregulated by RA treatment</td><td>71</td><td>14</td><td>85</td></tr><tr><td>Downregulated by RA treatment</td><td>16</td><td>132</td><td>151</td></tr><tr><td>Total</td><td>87</td><td>149</td><td>233</td></tr></table> |
af753c587e401fa38d39ab7e2a29990dd85b9cee68ff289a1ee09396b7077482.png | simple | <table><tr><td>Characteristics</td><td><i>n</i> (%)</td></tr><tr><td>Patient factors</td><td></td></tr><tr><td>Age (years)</td><td></td></tr><tr><td> ≥ 50</td><td>68 (30.9)</td></tr><tr><td> < 50</td><td>152 (69.1)</td></tr><tr><td>Gender</td><td></td></tr><tr><td> Male</td><td>167 (75.9)</td></tr><tr><td> Fem... | <table><tr><td>Characteristics</td><td>n (%)</td></tr><tr><td>Patient factors</td><td></td></tr><tr><td>Age (years)</td><td></td></tr><tr><td>≥ 50</td><td>68 (30.9)</td></tr><tr><td>< 50</td><td>152 (69.1)</td></tr><tr><td>Gender</td><td></td></tr><tr><td>Male</td><td>167 (75.9)</td></tr><tr><td>Female</td><td>53 (24.1... | <table><tr><td>1</td><td>.0)</td></tr><tr><td>N2</td><td>40 (18.2)</td></tr><tr><td>N3</td><td>18 (8.2)</td></tr><tr><td>Treatment factors</td><td></td></tr><tr><td>chemotherapy</td><td></td></tr><tr><td>Yes</td><td>190 (86.4)</td></tr><tr><td>No</td><td>30 (13.6)</td></tr></table> |
1e3d063bd2a22f6d1f3e4a4518b4b8875d54e4ba9ea94bb9cd42726210c2712e.png | simple | <table><tr><td>Group</td><td>Variable</td><td>Lambda</td><td>F</td><td>DF1</td><td>DF2</td><td><i>p</i>-value</td></tr><tr><td>SD-Risk</td><td>IFN</td><td>0.4841</td><td>17.5871</td><td>2</td><td>33</td><td>< 0.0001</td></tr><tr><td>SD-Risk</td><td>IL-2</td><td>0.3719</td><td>27.8637</td><td>2</td><td>33</td><td><... | <table><tr><td>Group</td><td>Variable</td><td>Lambda</td><td>F</td><td>DF1</td><td>DF2</td><td>p-value</td></tr><tr><td>SD-Risk</td><td>IFN</td><td>0.4841</td><td>17.5871</td><td>2</td><td>33</td><td>< 0.0001</td></tr></table> | <table><tr><td>Group</td><td>Variable</td><td>Lambda</td><td>F</td><td>DF1</td><td>DF2</td><td>p-value</td></tr><tr><td>SD-Risk</td><td>IL-2</td><td>0.3719</td><td>27.8637</td><td>2</td><td>33</td><td>< 0.0001</td></tr><tr><td>SD-Risk</td><td>IL-10</td><td>0.6091</td><td>10.5889</td><td>2</td><td>33</td><td>0.0003</td>... |
b8be3d5b9226ae98763531e3cc05f3d194628d6863e351cb90e0558a871369fa.png | simple | <table><tr><td>line</td><td>gene copy number</td></tr><tr><td>WT</td><td>0</td></tr><tr><td>Sox23</td><td>6 (12 homozygous)</td></tr><tr><td>Sox42</td><td>1 (2 homozygous)</td></tr><tr><td>Sox44</td><td>2 (4 homozygous)</td></tr></table> | <table><tr><td>line</td></tr><tr><td>WT</td></tr><tr><td>Sox23</td></tr><tr><td>Sox42</td></tr><tr><td>Sox44</td></tr></table> | <table><tr><td>gene copy number</td></tr><tr><td>0</td></tr><tr><td>6 (12 homozygous)</td></tr><tr><td>1 (2 homozygous)</td></tr><tr><td>2 (4 homozygous)</td></tr></table> |
3131f597fe5d7c6831f472a1fe5bf587cb8920fc9a4e5c1ef2246381a02416a0.png | simple | <table><tr><td></td><td>Skill 1</td><td>Skill 2</td><td>Skill 3</td><td>Skill 4</td><td>Skill 5</td><td>Total/Avg</td><td>Skill 6</td></tr><tr><td>Pre-workshop (n = 12)</td><td>3.5</td><td>4.3</td><td>3.8</td><td>2.8</td><td>2.3</td><td>16.7/3.3</td><td>3.5</td></tr><tr><td>Post-workshop (n = 7)</td><td>4.6</td><td>5.0... | <table><tr><td></td><td>Skill 1</td><td>Skill 2</td><td>Skill 3</td><td>Skill 4</td><td>Skill 5</td><td>Total/Avg</td><td>Skill 6</td></tr></table> | <table><tr><td>Pre-workshop (n = 12)</td><td>3.5</td><td>4.3</td><td>3.8</td><td>2.8</td><td>2.3</td><td>16.7/3.3</td><td>3.5</td></tr><tr><td>Post-workshop (n = 7)</td><td>4.6</td><td>5.0</td><td>4.4</td><td>4.7</td><td>2.6</td><td>21.3/4.3</td><td>2.0</td></tr><tr><td>p-value</td><td><0.01</td><td><0.05</td><td>0.18<... |
546526ada8af73eb8b1a7608e2cf49686977324b40c7dcd68f7e33b2a3c80b1d.png | simple | <table><tr><td>Index</td><td>Placebo group</td><td>Zaleplon 10 mg group</td><td>Zaleplon 15 mg group</td></tr><tr><td>Scores of SQS</td><td>3.75 ± 1.04</td><td>5.38 ± 0.92<sup>**</sup></td><td>6.00 ± 0.76<sup>**</sup></td></tr><tr><td>Scores of SDS</td><td>3.25 ± 1.04</td><td>4.62 ± 1.41<sup>*<... | <table><tr><td>Index</td><td>Placebo group</td><td>Zaleplon 10 mg group</td><td>Zaleplon 15 mg group</td></tr><tr><td>Scores of SQS</td><td>3.75 ± 1.04</td><td>5.38 ± 0.92**</td><td>6.00 ± 0.76**</td></tr></table> | <table><tr><td>Index</td><td>Placebo group</td><td>Zaleplon 10 mg group</td><td>Zaleplon 15 mg group</td></tr><tr><td>Scores of SDS</td><td>3.25 ± 1.04</td><td>4.62 ± 1.41*</td><td>6.12 ± 0.83**∆</td></tr><tr><td>Scores of SSS</td><td>2.38 ± 0.92</td><td>2.12 ± 0.64</td><td>2.38 ± 0.92</td></tr></table> |
a97b1dea321e4959385b0c3c7724ccce8bc379b880263c44c67aba9d2e1544af.png | simple | <table><tr><td><i>Characteristic</i></td><td><i>No. of patients</i></td><td><i>%</i></td></tr><tr><td>Patients evaluable</td><td>40</td><td>100</td></tr><tr><td>Age, years</td><td></td><td></td></tr><tr><td> Median</td><td>65</td><td></td></tr><tr><td> Range</td><td>34–75</td><td></td></tr><tr><td>Sex</td><td></t... | <table><tr><td>Characteristic</td><td>No. of patients</td><td>%</td></tr><tr><td>Patients evaluable</td><td>40</td><td>100</td></tr><tr><td>Age, years</td><td></td><td></td></tr><tr><td>Median</td><td>65</td><td></td></tr><tr><td>Range</td><td>34–75</td><td></td></tr><tr><td>Sex</td><td></td><td></td></tr></table> | <table><tr><td>Characteristic</td><td>No. of patients</td><td>%</td></tr><tr><td>Male</td><td>24</td><td>60</td></tr><tr><td>Female</td><td>16</td><td>40</td></tr><tr><td>ECOG PS</td><td></td><td></td></tr><tr><td>0</td><td>6</td><td>15</td></tr><tr><td>1</td><td>27</td><td>67.5</td></tr><tr><td>2</td><td>7</td><td>17.... |
465f25e16086d4dac57994d374e6e51ddac600e80d821e1de256610b56e32983.png | simple | <table><tr><td>Patient</td><td>Karyotype/Molecular lesion(s)</td><td>FAB subgroup</td><td>Age at diagnosis</td><td>IDO1 status</td><td>CR</td><td>Relapse</td><td>Alive</td></tr><tr><td>UPN #1</td><td>Normal</td><td>M2</td><td>13.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>UPN #2</td><td>t(8;2... | <table><tr><td>Patient</td><td>Karyotype/Molecular lesion(s)</td></tr><tr><td>UPN #1</td><td>Normal</td></tr><tr><td>UPN #2</td><td>t(8;21) (q22;q22)</td></tr><tr><td>UPN #3</td><td>Normal</td></tr><tr><td>UPN #4</td><td>Normal</td></tr><tr><td>UPN #5</td><td>Normal</td></tr><tr><td>UPN #6</td><td>Normal</td></tr><tr><... | <table><tr><td>FAB subgroup</td><td>Age at diagnosis</td><td>IDO1 status</td><td>CR</td><td>Relapse</td><td>Alive</td></tr><tr><td>M2</td><td>13.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>M2</td><td>13.0</td><td>Negative</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>M1</td><td>10.0</td... |
108caffb46f5d2d3b9e391f68e12c6627a9f1696d012fc7506f47a279b244189.png | complex | <table><tr><td></td><td colspan="2">Sock-only</td><td colspan="2">Shod</td></tr><tr><td>Subject</td><td>r</td><td>nMAD</td><td>r</td><td>nMAD</td></tr><tr><td>1</td><td>0.91</td><td>0.09</td><td>0.59</td><td>0.23</td></tr><tr><td>2</td><td>0.77</td><td>0.16</td><td>0.56</td><td>0.22</td></tr><tr><td>3</td><td>0.84</td>... | <table><tr><td></td><td colspan="2">Sock-only</td><td colspan="2">Shod</td></tr><tr><td>Subject</td><td>r</td><td>nMAD</td><td>r</td><td>nMAD</td></tr><tr><td>1</td><td>0.91</td><td>0.09</td><td>0.59</td><td>0.23</td></tr><tr><td>2</td><td>0.77</td><td>0.16</td><td>0.56</td><td>0.22</td></tr><tr><td>3</td><td>0.84</td>... | <table><tr><td>5</td><td>0.79</td><td>0.16</td><td>0.39</td><td>0.27</td></tr><tr><td>6</td><td>0.92</td><td>0.1</td><td>0.87</td><td>0.12</td></tr><tr><td>7</td><td>0.85</td><td>0.14</td><td>0.83</td><td>0.13</td></tr><tr><td>8</td><td>0.92</td><td>0.09</td><td>0.8</td><td>0.15</td></tr><tr><td>9</td><td>0.65</td><td>... |
1bb88fd1455395a16cff183d37599c390cee3b1b0af5930f889f36b37f061cb2.png | complex | <table><tr><td rowspan="2">Patient</td><td colspan="2">Before</td><td colspan="2">2 months</td><td colspan="2">6 months</td><td colspan="2">1 year</td></tr><tr><td>Right<sup>a</sup></td><td>Left<sup>b</sup></td><td>Right</td><td>Left</td><td>Right</td><td>Left</td><td>Right</td><td>Left</td></tr><tr><td> </td><td colsp... | <table><tr><td rowspan="2">Patient</td><td colspan="2">Before</td><td colspan="2">2 months</td><td colspan="2">6 months</td><td colspan="2">1 year</td></tr><tr><td>Righta</td><td>Leftb</td><td>Right</td><td>Left</td><td>Right</td><td>Left</td><td>Right</td><td>Left</td></tr><tr><td></td><td colspan="8">Biceps brachii m... | <table><tr><td>12</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.00</td><td>0.51</td><td>0.42</td></tr><tr><td>14</td><td>0.55</td><td>0.00</td><td>0.62</td><td>0.38</td><td>2.14</td><td>1.39</td><td>1.07</td><td>0.66</td></tr><tr><td>16</td><td>0.00</td><td>0.00</td><td>0.85</td><td>0.76</t... |
1add04ad3d4466031d7bdd5af31027c428a1c6f028242e592dba1e3960a1317a.png | complex | <table><tr><td>Age range</td><td>Count<sup>a</sup></td><td>ERP<sup>b</sup></td><td>Rate<sup>c</sup></td><td>Ratio<sup>d</sup></td><td colspan="2">95 % CI</td></tr><tr><td>4</td><td>7,594</td><td>72,820</td><td>10.4</td><td>0.26</td><td>0.26</td><td>0.26</td></tr><tr><td>5–9</td><td>100,787</td><td>340,503</td><td... | <table><tr><td>Age range</td><td>Counta</td><td>ERPb</td><td>Ratec</td><td>Ratiod</td><td colspan="2">95 % CI</td></tr><tr><td>4</td><td>7,594</td><td>72,820</td><td>10.4</td><td>0.26</td><td>0.26</td><td>0.26</td></tr><tr><td>5–9</td><td>100,787</td><td>340,503</td><td>29.6</td><td>0.74</td><td>0.74</td><td>0.74</td><... | <table><tr><td>10–14</td><td>132,965</td><td>330,448</td><td>40.2</td><td>1</td><td>1</td><td>1</td></tr><tr><td>15–19</td><td>81,910</td><td>355,117</td><td>23.1</td><td>0.57</td><td>0.57</td><td>0.57</td></tr><tr><td>20–24</td><td>47,831</td><td>412,009</td><td>11.6</td><td>0.29</td><td>0.29</td><td>0.29</td></tr><tr... |
31779a6c73bacce3fe6e376a74314056faa235bb6555c4b932c17ea33e7da319.png | complex | <table><tr><td rowspan="2"> </td><td colspan="2">Patients withAlzheimer's disease (n=21)</td><td rowspan="2"> </td><td colspan="2">Patients withfrontotemporal dementia (n=23)</td><td rowspan="2">U</td><td rowspan="2">Z</td><td rowspan="2">p*</td></tr><tr><td>M±SD</td><td>CI 95%</td><td>M±SD</td><td>CI 95%</td... | <table><tr><td rowspan="2"></td><td colspan="2">Patients withAlzheimer's disease (n=21)</td><td rowspan="2"></td><td colspan="2">Patients withfrontotemporal dementia (n=23)</td><td rowspan="2">U</td><td rowspan="2">Z</td><td rowspan="2">p*</td></tr><tr><td>M±SD</td><td>CI 95%</td><td>M±SD</td><td>CI 95%</td></tr><tr><t... | <table><tr><td rowspan="2"></td><td colspan="2">Patients withAlzheimer's disease (n=21)</td><td rowspan="2"></td><td colspan="2">Patients withfrontotemporal dementia (n=23)</td><td rowspan="2">U</td><td rowspan="2">Z</td><td rowspan="2">p*</td></tr><tr><td>M±SD</td><td>CI 95%</td><td>M±SD</td><td>CI 95%</td></tr><tr><t... |
61015fa3438e3f6f3d7105aace6b5df60ab2f5d3acb3e7632bfe8dd12c07e5c0.png | complex | <table><tr><td rowspan="2">Concentration range (pg/g lipid)</td><td colspan="2">Second-order (equivalent to minus change in apparent elimination rate in 2006)</td><td colspan="2">First-order (equivalent to minus apparent elimination rate)</td></tr><tr><td>coefficient</td><td><i>p</i>-value</td><td>coefficient</td><td><... | <table><tr><td rowspan="2">Concentration range (pg/g lipid)</td><td colspan="2">Second-order (equivalent to minus change in apparent elimination rate in 2006)</td><td colspan="2">First-order (equivalent to minus apparent elimination rate)</td></tr><tr><td>coefficient</td><td>p-value</td><td>coefficient</td><td>p-value<... | <table><tr><td rowspan="2">Concentration range (pg/g lipid)</td><td colspan="2">Second-order (equivalent to minus change in apparent elimination rate in 2006)</td><td colspan="2">First-order (equivalent to minus apparent elimination rate)</td></tr><tr><td>coefficient</td><td>p-value</td><td>coefficient</td><td>p-value<... |
b82b74ede38db7487e6946fe4c11597b8ba733ef06042b74b49534376e8bcebe.png | complex | <table><tr><td><i>N</i> = 1352</td><td>Non-responders <i>n</i> = 909</td><td>Responders <i>n</i> = 443</td><td><i>p</i> value</td></tr><tr><td>Women, <i>n</i> (%)</td><td>520 (57)</td><td>273 (62)</td><td>0.12 A</td></tr><tr><td>Age, average years (SD)</td><td>41.3 (11.8)</td><td>44.4 (10.8)</td><td>0.05 B</td></tr><tr... | <table><tr><td>N = 1352</td><td>Non-responders n = 909</td><td>Responders n = 443</td><td>p value</td></tr><tr><td>Women, n (%)</td><td>520 (57)</td><td>273 (62)</td><td>0.12 A</td></tr><tr><td>Age, average years (SD)</td><td>41.3 (11.8)</td><td>44.4 (10.8)</td><td>0.05 B</td></tr><tr><td>Work n (%)</td><td></td><td></... | <table><tr><td>N = 1352</td><td>Non-responders n = 909</td><td>Responders n = 443</td></tr><tr><td>Non-RTW</td><td>309 (34)</td><td>146 (33)</td></tr><tr><td>RTW</td><td>548 (60)</td><td>273 (62)</td></tr><tr><td>Old age and disability pension</td><td>50 (6)</td><td>22 (5)</td></tr><tr><td>Died</td><td>2 (0)</td><td>2 ... |
aa44cf6c3f9a961ef2307e446b7253cab3fc474c2e7a9ad91b1d682d92c8efb9.png | complex | <table><tr><td></td><td colspan="2">Perianal disease prior to pregnancy n = 27</td><td colspan="2">No perianal disease prior to pregnancy n = 87</td></tr><tr><td>Mode of childbirth</td><td>Vaginal delivery n (%)</td><td>Caesarean section n (%)</td><td>Vaginal delivery n (%)</td><td>Caesarean section n (%)</td></tr><tr>... | <table><tr><td></td><td colspan="2">Perianal disease prior to pregnancy n = 27</td><td colspan="2">No perianal disease prior to pregnancy n = 87</td></tr><tr><td>Mode of childbirth</td><td>Vaginal delivery n (%)</td><td>Caesarean section n (%)</td><td>Vaginal delivery n (%)</td><td>Caesarean section n (%)</td></tr><tr>... | <table><tr><td>Progression perianal disease ≤ 2 years post partum:</td><td>2 (18)</td><td>5 (31)</td><td>3 (5)</td><td>3 (14)</td></tr><tr><td>- Yes</td><td>9 (82)</td><td>9 (56)</td><td>58(94)</td><td>18 (86)</td></tr><tr><td>- No</td><td>0 (0)</td><td>2 (13)</td><td>5 (1)</td><td>0 (0)</td></tr><tr><td>- Not applicab... |
21d214ad1e4e3238c3aa6ad4b4b716adae35e514a724e799de69cc970660cfc4.png | simple | <table><tr><td>Peptide</td><td>Sequence</td><td>Mw</td><td>pI<sup>1</sup></td><td>Net charge</td><td>Mean hydrophobicity<sup>2</sup></td></tr><tr><td>KHN20</td><td>KHNLGHGHKHERDQGHGHQR</td><td>2365.5</td><td>9.99</td><td>+2</td><td>−4.91</td></tr><tr><td>GHG20</td><td>GHGLGHGHEQQHGLGHGHKF</td><td>2127.2</td><td>7... | <table><tr><td>Peptide</td><td>Sequence</td><td>Mw</td></tr><tr><td>KHN20</td><td>KHNLGHGHKHERDQGHGHQR</td><td>2365.5</td></tr><tr><td>GHG20</td><td>GHGLGHGHEQQHGLGHGHKF</td><td>2127.2</td></tr><tr><td>GHG21</td><td>GHGHKFKLDDDLEHQGGHVLD</td><td>2354.5</td></tr><tr><td>GGH20</td><td>GGHVLDHGHKHKHGHGHGKH</td><td>2169.3<... | <table><tr><td>pI1</td><td>Net charge</td><td>Mean hydrophobicity2</td></tr><tr><td>9.99</td><td>+2</td><td>−4.91</td></tr><tr><td>7.21</td><td>0</td><td>−2.01</td></tr><tr><td>5.63</td><td>−3</td><td>−2.32</td></tr><tr><td>9.70</td><td>+2</td><td>−3.44</td></tr><tr><td>10.78</td><td>+7</td><td>−5.91</td></tr><tr><td>1... |
483d9bc63d82a56209d473d293ba38f1616315880c3d6c1e42c576e119a41735.png | simple | <table><tr><td>Matching phase</td><td>Type of match</td><td>Number linked</td><td>%</td></tr><tr><td>1</td><td>Child’s first, middle, and last name & dob and mother’s dob</td><td>5282</td><td>2.6 %</td></tr><tr><td>2</td><td>Child’s first, middle initial, and last name & dob and mother’s... | <table><tr><td>Matching phase</td><td>Type of match</td><td>Number linked</td><td>%</td></tr></table> | <table><tr><td>1</td><td>Child’s first, middle, and last name & dob and mother’s dob</td><td>5282</td><td>2.6 %</td></tr><tr><td>2</td><td>Child’s first, middle initial, and last name & dob and mother’s dob</td><td>32094</td><td>16.0 %</td></tr><tr><td>3</td><td>Child’s first, middle, and last name & dob</td><td>3035</... |
1c8c786e697d73021eaa53b2981f842209367d6595154fc3c3110bd98e9f27e0.png | simple | <table><tr><td>Number</td><td>Authors, year</td><td>c</td><td>Age, sex</td><td>Period (years)</td><td>symptoms</td><td>Preoperative lab</td><td>Treatment</td><td>Histological diagnosis</td><td>Outcomes</td></tr><tr><td>1</td><td>Boriani et al, 1978 [8]</td><td>S1-3</td><td>18, M</td><td>DNMI</td><td>Bone pain, weakness... | <table><tr><td>Number</td><td>Authors, year</td><td>c</td><td>Age, sex</td><td>Period (years)</td><td>symptoms</td><td>Preoperative lab</td></tr><tr><td>1</td><td>Boriani et al, 1978 [8]</td><td>S1-3</td><td>18, M</td><td>DNMI</td><td>Bone pain, weakness</td><td>Hypophosphatemia, elevated ALP</td></tr><tr><td>2</td><td... | <table><tr><td>Treatment</td><td>Histological diagnosis</td><td>Outcomes</td></tr><tr><td>Complete resection, radiotherapy</td><td>Osteosarcoma</td><td>NOLF</td></tr><tr><td>Complete resection, supplementation of vitamin D, phosphate, and calcium</td><td>Neuroendocrine tumor</td><td>NOLF</td></tr><tr><td>Partial resect... |
1d6c6d54bc931bbc726f4d9068f717a7b7a9bc930cefed5207aa0fa6357472e4.png | complex | <table><tr><td rowspan="3">Antibiotics<sup>a</sup></td><td rowspan="3">Extracts concentration<sup>b</sup></td><td colspan="9">Bacteria, MIC (μg/mL) and modulating factors (in bracket)</td><td rowspan="3">Modulating effect (%)<sup>b</sup></td></tr><tr><td colspan="3"><i>E. coli</i></td><td colspan="3"><i>E. aerogen... | <table><tr><td rowspan="3">Antibioticsa</td><td rowspan="3">Extracts concentrationb</td><td colspan="9">Bacteria, MIC (μg/mL) and modulating factors (in bracket)</td><td rowspan="3">Modulating effect (%)b</td></tr><tr><td colspan="3">E. coli</td><td colspan="3">E. aerogenes</td><td>K. pneumoniae</td><td>P. stuartuii</t... | <table><tr><td rowspan="2">CIP</td><td>MIC/2</td><td>≤0.5 (na)</td><td>≤0.5 (na)</td><td>64(2)</td><td>32 (2)</td><td>128 (1)</td><td>1 (1)</td><td>64 (2)</td><td>1 (1)</td><td>32 (1)</td><td>33.33</td></tr><tr><td>MIC/4</td><td>≤0.5 (na)</td><td>≤0.5 (na)</td><td>128(1)</td><td>64 (1)</td><td>128 (1)</td><td>1 (1)</td... |
8d262637ec2bd2cf4019abcbcb92951ebf038969a6655cc8d7cabf530861342b.png | simple | <table><tr><td>Period</td><td>No. of regions</td><td>STR-realigner</td><td>ReviSTER</td><td>IndelRealigner</td><td>--realign option</td><td>Original BAM</td></tr><tr><td>1</td><td>5345</td><td><underline>2.477</underline></td><td>2.695</td><td>6.017</td><td>6.009</td><td>6.009</td></tr><tr><td>2</td><td>1160</td><td><u... | <table><tr><td>Period</td><td>No. of regions</td><td>STR-realigner</td><td>ReviSTER</td><td>IndelRealigner</td><td>--realign option</td><td>Original BAM</td></tr><tr><td>1</td><td>5345</td><td>2.477</td><td>2.695</td><td>6.017</td><td>6.009</td><td>6.009</td></tr><tr><td>2</td><td>1160</td><td>3.545</td><td>3.740</td><... | <table><tr><td>Total</td><td>9595</td><td>3.116</td><td>3.309</td><td>6.752</td><td>6.727</td><td>6.732</td></tr></table> |
2314ae9f3cbe088777a86993d3c7863ec9dae7b4e78a27677351688d054de18a.png | simple | <table><tr><td>Variables</td><td><i>β</i></td><td><i>P </i>value</td><td>OR (95% CI)</td></tr><tr><td>Age</td><td>0.428</td><td><0.001</td><td>1.53 (1.35–1.75)</td></tr><tr><td>HR</td><td>0.859</td><td><0.001</td><td>2.36 (2.09–2.67)</td></tr><tr><td>BMI</td><td>0.273</td><td>0.001</td><td>1.31 (... | <table><tr><td>Variables</td><td>β</td><td>P value</td><td>OR (95% CI)</td></tr><tr><td>Age</td><td>0.428</td><td><0.001</td><td>1.53 (1.35–1.75)</td></tr><tr><td>HR</td><td>0.859</td><td><0.001</td><td>2.36 (2.09–2.67)</td></tr><tr><td>BMI</td><td>0.273</td><td>0.001</td><td>1.31 (1.13–1.53)</td></tr><tr><td>WC</td><t... | <table><tr><td>DBP</td><td>0.019</td><td>0.001</td><td>1.02 (1.01–1.03)</td></tr><tr><td>FPG</td><td>0.450</td><td><0.001</td><td>1.57 (1.39–1.78)</td></tr><tr><td>PBG</td><td>0.475</td><td><0.001</td><td>1.61 (1.41–1.83)</td></tr><tr><td>IR</td><td>0.279</td><td><0.001</td><td>1.32 (1.20–1.46)</td></tr><tr><td>TG</td>... |
c2f55c30d3aa8f10229f888d93310dd098f4d07dc90803f295703f636a2c0e04.png | complex | <table><tr><td></td><td colspan="6">Year</td><td></td><td></td></tr><tr><td></td><td colspan="2">1992 (<i>n = </i>321)</td><td colspan="2">2000 (<i>n = </i>433)</td><td colspan="2">2008 (<i>n = </i>607)</td><td colspan="2">Trend</td></tr><tr><td></td><td>%</td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td><td><... | <table><tr><td></td><td colspan="6">Year</td><td></td><td></td></tr><tr><td></td><td colspan="2">1992 (n = 321)</td><td colspan="2">2000 (n = 433)</td><td colspan="2">2008 (n = 607)</td><td colspan="2">Trend</td></tr><tr><td></td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>χ2 (d.f. = 1)</td><td>P</t... | <table><tr><td></td><td colspan="6">Year</td><td></td><td></td></tr><tr><td>Bad news</td><td>76</td><td>94</td><td>73</td><td>74</td><td>48</td><td>91</td><td>26.653</td><td>< 0.001</td></tr><tr><td>Understanding mental illness</td><td>6</td><td>8</td><td>14</td><td>14</td><td>24</td><td>45</td><td>17.096</td><td>< 0.0... |
cb17a289922844333b0e6ca44260abc1cb959f2d067264fa51a35124da008bba.png | complex | <table><tr><td rowspan="2">Trait (nm)</td><td colspan="2">Standard diet</td><td colspan="2">Standard diet + ATRA</td></tr><tr><td>SHR</td><td>SHR-<i>Lx</i></td><td>SHR</td><td>SHR-<i>Lx</i></td></tr><tr><td></td><td>(n = 7)</td><td>(n = 7)</td><td>(n = 7)</td><td>(n = 8)</td></tr><tr><td>VLDL-TG</td><td>49.51 ± 0.... | <table><tr><td>Trait (nm)</td><td colspan="2">Standard diet</td><td colspan="2">Standard diet + ATRA</td></tr></table> | <table><tr><td>Trait (nm)</td><td>SHR</td><td>SHR-Lx</td><td>SHR</td><td>SHR-Lx</td></tr><tr><td></td><td>(n = 7)</td><td>(n = 7)</td><td>(n = 7)</td><td>(n = 8)</td></tr><tr><td>VLDL-TG</td><td>49.51 ± 0.45</td><td>48.24 ± 0.49</td><td>48.48 ± 0.68</td><td>50.27 ± 0.41*,a</td></tr><tr><td>LDL-C</td><td>21.45 ± 0.25</t... |
8de1285b04d9bbcdbe6075904c78dbbf8d7e09f8685023507e48bd9e45cc227a.png | complex | <table><tr><td>Method of risk assessment</td><td>Definition</td><td>Advantages</td><td>Limitations</td></tr><tr><td>Clinical prediction rules</td><td>The use of a scoring system based on patient- or procedure-related risk factors to quantify risk</td><td>Often cost-neutral</td><td>Estimates population risk for patient ... | <table><tr><td>Method of risk assessment</td><td>Definition</td><td>Advantages</td><td>Limitations</td></tr><tr><td>Clinical prediction rules</td><td>The use of a scoring system based on patient- or procedure-related risk factors to quantify risk</td><td>Often cost-neutral</td><td>Estimates population risk for patient ... | <table><tr><td>Method of risk assessment</td><td>Definition</td><td>Advantages</td><td>Limitations</td></tr><tr><td></td><td></td><td></td><td>Poor sensitivity and specificity for prediction of morbidity and mortality on an individual patient basis[33,40]</td></tr><tr><td>Lee Revised Cardiac Risk Index (RCRI)</td><td>S... |
7dbae20bf417d120566efbf5e1069658b3102a91265d7544a4148bd8ea269ba7.png | simple | <table><tr><td>Polymorphism</td><td>Reference allele homozygote</td><td>Heterozygote</td><td>Variant allele homozygote</td></tr><tr><td>PAI-2 (<i>SERPINB</i>, rs6095)</td><td></td><td></td><td></td></tr><tr><td>Event Rate (%)</td><td>34.7</td><td>14.6</td><td>6.7</td></tr><tr><td>Number of patients</td><td>72</td><td>4... | <table><tr><td>Polymorphism</td><td>Reference allele homozygote</td><td>Heterozygote</td><td>Variant allele homozygote</td></tr><tr><td>PAI-2 (SERPINB, rs6095)</td><td></td><td></td><td></td></tr><tr><td>Event Rate (%)</td><td>34.7</td><td>14.6</td><td>6.7</td></tr><tr><td>Number of patients</td><td>72</td><td>48</td><... | <table><tr><td>Number of patients (%)</td><td>67.9</td><td>29.3</td><td>2.9</td></tr><tr><td>CETP (CETP, rs708272)*</td><td></td><td></td><td></td></tr><tr><td>Event Rate (%)</td><td>14.9</td><td>26.4</td><td>33.3</td></tr><tr><td>Number of patients</td><td>47</td><td>72</td><td>24</td></tr><tr><td>Number of patients (... |
c790e2463e5e7b3dfcb06fd98a5c88fd693e3ca1e91ce2133f2d1e9ba2d18483.png | simple | <table><tr><td>Group</td><td>Location</td><td>Gender</td><td>Age range (years)</td><td>Number of participants</td></tr><tr><td>One</td><td>ROI</td><td>Female</td><td>20-29</td><td>8</td></tr><tr><td>Two</td><td>ROI</td><td>Female</td><td>30-40</td><td>9</td></tr><tr><td>Three</td><td>ROI</td><td>Male</td><td>29-39</td>... | <table><tr><td>Group</td><td>Location</td><td>Gender</td><td>Age range (years)</td><td>Number of participants</td></tr><tr><td>One</td><td>ROI</td><td>Female</td><td>20-29</td><td>8</td></tr></table> | <table><tr><td>Group</td><td>Location</td><td>Gender</td><td>Age range (years)</td><td>Number of participants</td></tr><tr><td>Two</td><td>ROI</td><td>Female</td><td>30-40</td><td>9</td></tr><tr><td>Three</td><td>ROI</td><td>Male</td><td>29-39</td><td>8</td></tr><tr><td>Four</td><td>NI</td><td>Male</td><td>29-59</td><t... |
9719396d944e667711b48e627cccebac09e62229ec8e1450c5732639d36c45bf.png | complex | <table><tr><td>Gene/Gene Cluster Name</td><td>Localization within the POC9 Draft Genome Sequence(GenBank acc. no.)</td><td>Protein</td><td>Best BLAST Hits:[% Identity] Organism(GeneBank acc. no.)</td><td>Predicted Antimicrobial Resistance Profile</td><td>Tested Antibiotics</td><td>Profile</td></tr><tr><td rowspan="2"><... | <table><tr><td>Gene/Gene Cluster Name</td><td>Localization within the POC9 Draft Genome Sequence(GenBank acc. no.)</td><td>Protein</td><td>Best BLAST Hits:[% Identity] Organism(GeneBank acc. no.)</td><td>Predicted Antimicrobial Resistance Profile</td><td>Tested Antibiotics</td><td>Profile</td></tr><tr><td rowspan="2">g... | <table><tr><td rowspan="2">tetG-tetR</td><td rowspan="2">contig00014 (QGST01000014.1)coordinates: 7148–9063</td><td>Tet(A/B/C) family MFS transporter</td><td>[87%] Ochrobactrum oryzae(WP_104755825)</td><td rowspan="2">tetracyclines</td><td rowspan="2">TE</td><td rowspan="2">S</td></tr><tr><td>transcriptional regulator ... |
6aa169f9d5fbada5f015c1d047606c96fbc7b18a28eeeefc48feb4f09b4b2aa7.png | complex | <table><tr><td></td><td>Fixed effects model</td><td>Growth curve model 1</td><td>Growth curve model 2</td></tr><tr><td>Fixed part</td><td></td><td></td><td></td></tr><tr><td> <i>Intercept</i></td><td>0.820 (0.756 to 0.884)</td><td>0.823 (0.779 to 0.866)</td><td>0.830 (0.791 to 0.87)</td></tr><tr><td> <i>Age-centred (li... | <table><tr><td></td><td>Fixed effects model</td><td>Growth curve model 1</td><td>Growth curve model 2</td></tr><tr><td>Fixed part</td><td></td><td></td><td></td></tr><tr><td>Intercept</td><td>0.820 (0.756 to 0.884)</td><td>0.823 (0.779 to 0.866)</td><td>0.830 (0.791 to 0.87)</td></tr><tr><td>Age-centred (linear term)</... | <table><tr><td></td><td>Fixed effects model</td><td>Growth curve model 1</td><td>Growth curve model 2</td></tr><tr><td>Level 1 (wave)</td><td></td><td></td><td></td></tr><tr><td>Intercept</td><td></td><td>0.020</td><td>0.020</td></tr><tr><td>N observations (level 1)</td><td>27 509</td><td>27 509</td><td>27 509</td></tr... |
ccaa30b2b79fc120081d5d0f41702613b88cac6b56335baac2ee9126bd902fbb.png | simple | <table><tr><td>Characteristic</td><td>N</td><td>%</td></tr><tr><td>Age</td><td> </td><td> </td></tr><tr><td>< = 50</td><td>22</td><td>13.3</td></tr><tr><td>51-60</td><td>42</td><td>25.3</td></tr><tr><td>61-70</td><td>57</td><td>34.3</td></tr><tr><td>> 70</td><td>45</td><td>27.1</td></tr><tr><td>Tumor (T)</td><td>... | <table><tr><td>Characteristic</td></tr><tr><td>Age</td></tr><tr><td>< = 50</td></tr><tr><td>51-60</td></tr><tr><td>61-70</td></tr><tr><td>> 70</td></tr><tr><td>Tumor (T)</td></tr><tr><td>T1</td></tr><tr><td>T2</td></tr><tr><td>T3</td></tr><tr><td>T4</td></tr><tr><td>Lymph nodes (N)</td></tr><tr><td>N0</td></tr><tr><td>... | <table><tr><td>N</td><td>%</td></tr><tr><td></td><td></td></tr><tr><td>22</td><td>13.3</td></tr><tr><td>42</td><td>25.3</td></tr><tr><td>57</td><td>34.3</td></tr><tr><td>45</td><td>27.1</td></tr><tr><td></td><td></td></tr><tr><td>68</td><td>41</td></tr><tr><td>40</td><td>24.1</td></tr><tr><td>34</td><td>20.5</td></tr><... |
79e181aa93eba88ac222ea123cb792b90ecdc7862e5cfb598ead0256edc4904b.png | simple | <table><tr><td></td><td>Month 1</td><td>Month 16</td><td>Month 21</td><td>Total sample<i>n</i> = 72</td></tr><tr><td>Decisions to be made, <i>n</i> (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Medical admission or treatment</td><td>17 (81)<sup>a</sup></td><td>12 (44)<sup>a</sup></td><td>8 (33)<sup>a</sup></... | <table><tr><td></td><td>Month 1</td><td>Month 16</td><td>Month 21</td><td>Total samplen = 72</td></tr><tr><td>Decisions to be made, n (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Medical admission or treatment</td><td>17 (81)a</td><td>12 (44)a</td><td>8 (33)a</td><td>37 (51)</td></tr><tr><td>Psychiatric adm... | <table><tr><td></td><td>Month 1</td><td>Month 16</td><td>Month 21</td><td>Total samplen = 72</td></tr><tr><td>Agreement status, n (%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Agreeing</td><td>5 (24)</td><td>15 (56)</td><td>12 (50)</td><td>32 (44)</td></tr><tr><td>Not agreeing(or unable to express a choice/n... |
81ee06e3d49c6d5e79b5b0194793bb6f3dff718b95f0d6bd127275843a7cac92.png | complex | <table><tr><td colspan="5">Food composition of major foods in Uganda (per 100 g of edible portion)</td></tr><tr><td>Food</td><td>Calories</td><td>Protein (g)</td><td colspan="2">Iron (Mg)</td></tr><tr><td>Finger millet</td><td>346</td><td>8.7</td><td colspan="2">4.0</td></tr><tr><td>Sorghum</td><td>354</td><td>10.2</td... | <table><tr><td colspan="5">Food composition of major foods in Uganda (per 100 g of edible portion)</td></tr><tr><td>Food</td><td>Calories</td><td>Protein (g)</td><td colspan="2">Iron (Mg)</td></tr><tr><td>Finger millet</td><td>346</td><td>8.7</td><td colspan="2">4.0</td></tr><tr><td>Sorghum</td><td>354</td><td>10.2</td... | <table><tr><td>Simsim</td><td>593</td><td>20.1</td><td colspan="2">9.8</td></tr><tr><td>Sweet Potato</td><td>166</td><td>1.3</td><td colspan="2">1.2</td></tr><tr><td colspan="5">Per capita of protein and calories derived from the major foods</td></tr><tr><td>Food</td><td colspan="2">Protein</td><td colspan="2">Calories... |
e671671fe066e5733268260f13cb36a8277c039eaccccd5b61f626a78359a3a7.png | complex | <table><tr><td rowspan="2">Cluster #</td><td colspan="5">Expression level</td></tr><tr><td>High</td><td>Medium high</td><td>Medium</td><td>Medium low</td><td>Low</td></tr><tr><td>1</td><td>Ribosome</td><td>Lumen</td><td>Lumen</td><td>Lumen</td><td>DNA repair/Stress response</td></tr><tr><td>2</td><td>Oxidative Phosphor... | <table><tr><td rowspan="2">Cluster #</td><td colspan="5">Expression level</td></tr><tr><td>High</td><td>Medium high</td><td>Medium</td><td>Medium low</td><td>Low</td></tr><tr><td>1</td><td>Ribosome</td><td>Lumen</td><td>Lumen</td><td>Lumen</td><td>DNA repair/Stress response</td></tr><tr><td>2</td><td>Oxidative Phosphor... | <table><tr><td></td><td>al subunits</td><td>components</td><td>Ankyrin repeats</td><td>ion</td><td> of differentiation</td></tr><tr><td>10</td><td>Protein folding</td><td>RNA splicing</td><td>tRNA</td><td>Zinc finger CH2</td><td>Nucleic acid binding</td></tr></table> |
1760b2a9a980613cd0d31f0518c69959cd5abeae1a41b7c004ec897f66ae1127.png | complex | <table><tr><td>Primary reference, Study, Country (secondary references)</td><td>Objectives</td><td>Design</td><td>Sample size</td><td>Patient population</td><td>Follow-up</td></tr><tr><td colspan="6">Treatment-related observational studies</td></tr><tr><td>Driessen 2008[68], Radboud University Registry, The Netherlands... | <table><tr><td>Primary reference, Study, Country (secondary references)</td><td>Objectives</td><td>Design</td><td>Sample size</td><td>Patient population</td><td>Follow-up</td></tr><tr><td colspan="6">Treatment-related observational studies</td></tr><tr><td>Driessen 2008[68], Radboud University Registry, The Netherlands... | <table><tr><td>Primary reference, Study, Country (secondary references)</td><td>Objectives</td><td>Design</td><td>Sample size</td><td>Patient population</td><td>Follow-up</td></tr><tr><td>Kane 2003[95], St. Vincent's University study, Ireland, (Kane 2003a[96])</td><td>Clinical presentation, outcome and prognosis of ear... |
e9b63f146dc955559d16fe04f4b008cc06ff86cee61a0a6a21294f06ccd8332c.png | complex | <table><tr><td rowspan="2">Characteristics</td><td>No OSA</td><td>Mild-Moderate OSA</td><td>Severe OSA</td><td rowspan="2"><i>p</i> value</td></tr><tr><td><i>n</i> = 10</td><td><i>n</i> = 33</td><td><i>n</i> = 34</td></tr><tr><td>Total sleep time (minutes)</td><td>288.2 ± 88.2</td><td>268.3 ± 80.7</td><td>253... | <table><tr><td rowspan="2">Characteristics</td><td>No OSA</td><td>Mild-Moderate OSA</td><td>Severe OSA</td><td rowspan="2">p value</td></tr><tr><td>n = 10</td><td>n = 33</td><td>n = 34</td></tr><tr><td>Total sleep time (minutes)</td><td>288.2 ± 88.2</td><td>268.3 ± 80.7</td><td>253.8 ± 74.6</td><td>0.207</td></tr></tab... | <table><tr><td>Sleep efficiency (%)</td><td>76.1 ± 22.9</td><td>75.8 ± 16.1</td><td>72.1 ± 18.0</td><td>0.506</td></tr><tr><td>AHI event. h−1</td><td>2.4 ± 1.5</td><td>16.2 ± 6.6</td><td>61.4 ± 20.0</td><td>0.001</td></tr><tr><td>ODI event. h−1</td><td>1.7 ± 1.7</td><td>14.5 ± 6.1</td><td>52.1 ± 22.8</td><td>0.001</td>... |
ecaa3f8b2afd8c6029196955bef614115131d03d423e995bc8434738abd43359.png | complex | <table><tr><td rowspan="2">Animal group</td><td colspan="2">Body weight (g)</td><td colspan="2">Blood glucose (mg/dL)</td></tr><tr><td>Before STZ injection</td><td>End experiment</td><td>Before drug injection</td><td>End experiment</td></tr><tr><td>Control (8)</td><td>270 ± 13.9 </td><td>276.25 ± 13.29</td><t... | <table><tr><td>Animal group</td><td colspan="2">Body weight (g)</td><td colspan="2">Blood glucose (mg/dL)</td></tr></table> | <table><tr><td>Animal group</td><td>Before STZ injection</td><td>End experiment</td><td>Before drug injection</td><td>End experiment</td></tr><tr><td>Control (8)</td><td>270 ± 13.9</td><td>276.25 ± 13.29</td><td>133 ± 33.41</td><td>132.87 ± 35.62</td></tr><tr><td>Vehicle (8)</td><td>260 ± 21.60</td><td>237.14 ± 24.97*<... |
0f11f0c50f89213400914c7a505147442058b668589b9430ede7aef5c13d8c07.png | simple | <table><tr><td>Symbol</td><td>Name</td><td>Function</td><td>Reference</td></tr><tr><td>PLK1</td><td>polo-like kinase 1</td><td>cell cycle regulation</td><td>[13-19]</td></tr><tr><td>CDK16</td><td>cyclin-dependent kinase 16</td><td>cell cycle regulation</td><td>[20]</td></tr><tr><td>RYK</td><td>receptor-like tyrosine ki... | <table><tr><td>Symbol</td><td>Name</td><td>Function</td><td>Reference</td></tr><tr><td>PLK1</td><td>polo-like kinase 1</td><td>cell cycle regulation</td><td>[13-19]</td></tr><tr><td>CDK16</td><td>cyclin-dependent kinase 16</td><td>cell cycle regulation</td><td>[20]</td></tr><tr><td>RYK</td><td>receptor-like tyrosine ki... | <table><tr><td>Symbol</td><td>Name</td><td>Function</td><td>Reference</td></tr><tr><td>AURKA</td><td>aurora kinase A</td><td>cell cycle regulation</td><td>[33,34]</td></tr><tr><td>BUB1</td><td>mitotic checkpoint serine/threonine kinase</td><td>cell cycle regulation</td><td>[35]</td></tr><tr><td>CDC7</td><td>cell divisi... |
8a938dcf98995c1cad36b196933af6ea2d61f6576d11c00cb0996bf830a2545c.png | complex | <table><tr><td> </td><td> </td><td colspan="3">Dietary supplementation<sup>a</sup></td><td colspan="3">Statistical significance of variance ratio (P)<sup>b</sup>, effects of</td></tr><tr><td> </td><td>Control</td><td>TTA</td><td>FO</td><td>TTA + FO</td><td>TTA</td><td>FO</td><td>TTA*FO</td></tr><tr><td>CPT-I</td><td>2.... | <table><tr><td></td><td></td><td colspan="3">Dietary supplementationa</td><td colspan="3">Statistical significance of variance ratio (P)b, effects of</td></tr><tr><td></td><td>Control</td><td>TTA</td><td>FO</td><td>TTA + FO</td><td>TTA</td><td>FO</td><td>TTA*FO</td></tr><tr><td>CPT-I</td><td>2.79 ± 0.26c</td><td>1.69 ±... | <table><tr><td>CPT-I (with malonyl-CoA)</td><td>1.89 ± 0.21</td><td>1.23 ± 0.28</td><td>1.77 ± 0.14</td><td>1.31 ± 0.13</td><td><0.001</td><td>0.73</td><td>0.14</td></tr><tr><td>CPT-II</td><td>10.79 ± 1.03</td><td>23.55 ± 3.15</td><td>12.40 ± 2.33</td><td>22.39 ± 4.32</td><td><0.001</td><td>0.82</td><td>0.15</td></tr><... |
85dbd38e4c22fe34329f26898b167873c62a81dece6b75b27f9de01171c94c2d.png | complex | <table><tr><td> </td><td colspan="2">D-dimer ≥10 <i>μ</i>g/mL after treatment</td><td> </td></tr><tr><td> </td><td>No</td><td>Yes</td><td><i>p</i><sup>∗</sup></td></tr><tr><td> </td><td>(<i>n</i> = 31)</td><td>(<i>n</i> = 21)</td><td> </td></tr><tr><td>Male sex</td><td>18 (58.1%)</td><td>10 (47.6%)</td... | <table><tr><td></td><td colspan="2">D-dimer ≥10 μg/mL after treatment</td><td></td></tr><tr><td></td><td>No</td><td>Yes</td><td>p∗</td></tr><tr><td></td><td>(n = 31)</td><td>(n = 21)</td><td></td></tr><tr><td>Male sex</td><td>18 (58.1%)</td><td>10 (47.6%)</td><td>0.458</td></tr><tr><td>Age, years</td><td>63 (55–71)</td... | <table><tr><td></td><td colspan="2">D-dimer ≥10 μg/mL after treatment</td><td></td></tr><tr><td></td><td>No</td><td>Yes</td><td>p∗</td></tr><tr><td></td><td>(n = 31)</td><td>(n = 21)</td><td></td></tr><tr><td>Warfarin</td><td>10 (32.3%)</td><td>16 (72.6%)</td><td></td></tr><tr><td>Cancer profiles</td><td></td><td></td>... |
2e223de9d2a4188ea3d600f4da5d81bb8f015ad92f14d270ecae7d7ae159a10a.png | simple | <table><tr><td>Generic name</td><td>Study drug name (Brand name)</td><td>Active ingredient content</td><td>Manufacturers/distributors</td></tr><tr><td>amlodipine besilate</td><td>Amlodin<sup>® </sup>tablets 2.5</td><td>containing 2.5 mg of amlodipine</td><td>Sumitomo Pharmaceuticals Co., Ltd.</td></tr><tr><td></td... | <table><tr><td>Generic name</td><td>Study drug name (Brand name)</td><td>Active ingredient content</td><td>Manufacturers/distributors</td></tr><tr><td>amlodipine besilate</td><td>Amlodin® tablets 2.5</td><td>containing 2.5 mg of amlodipine</td><td>Sumitomo Pharmaceuticals Co., Ltd.</td></tr></table> | <table><tr><td>Amlodin® tablets 5</td><td>containing 5 mg of amlodipine</td><td></td></tr><tr><td>Norvasc® tablets 2.5 mg</td><td>containing 2.5 mg of amlodipine</td><td>Pfizer Japan Inc.</td></tr><tr><td>Norvasc® tablets 5 mg</td><td>containing 5 mg of amlodipine</td><td></td></tr></table> |
0a9d75ddd91445ba6a219610e77e40ee6bf6ebcc81a85cc7e82d45983f98cc04.png | simple | <table><tr><td>BPG</td><td>Patient Eligibility Criteria </td><td>Participating Program Units</td></tr><tr><td>Asthma</td><td>Patients who present to the participating units with a primary or secondary diagnosis of asthma</td><td>Emergency, in-patient and medical units</td></tr><tr><td>Breastfeeding</td><td>Postpartum w... | <table><tr><td>BPG</td><td>Patient Eligibility Criteria</td><td>Participating Program Units</td></tr><tr><td>Asthma</td><td>Patients who present to the participating units with a primary or secondary diagnosis of asthma</td><td>Emergency, in-patient and medical units</td></tr></table> | <table><tr><td>BPG</td><td>Patient Eligibility Criteria</td><td>Participating Program Units</td></tr><tr><td>Breastfeeding</td><td>Postpartum women and their infants with a singleton birth, gestational age of 37 or more weeks, hospital length of stay for mother and infant 24 hours or more after birth, infant not delive... |
912b9b91fdaca3c74a75ca6d1cb893ea7d8a60f1059bd1b71d4691632ce9fa0d.png | simple | <table><tr><td>Organism</td><td>Precision</td><td>Recall</td><td>F-score</td></tr><tr><td>Mouse</td><td>0.77</td><td>0.81</td><td>0.79</td></tr><tr><td>Yeast</td><td>0.97</td><td>0.84</td><td>0.90</td></tr><tr><td>Fly</td><td>0.83</td><td>0.80</td><td>0.82</td></tr><tr><td>FlyAccept matches of synonyms associated to up... | <table><tr><td>Organism</td><td>Precision</td><td>Recall</td><td>F-score</td></tr></table> | <table><tr><td>Mouse</td><td>0.77</td><td>0.81</td><td>0.79</td></tr><tr><td>Yeast</td><td>0.97</td><td>0.84</td><td>0.90</td></tr><tr><td>Fly</td><td>0.83</td><td>0.80</td><td>0.82</td></tr><tr><td>FlyAccept matches of synonyms associated to up to 3 different Entrez Gene entries</td><td>0.74</td><td>0.83</td><td>0.79<... |
e65e582dc802d0364c209deb4409969b2d88f0a20ace377494eb5d13d4fcd674.png | simple | <table><tr><td>Command</td><td>Value</td><td>Description</td></tr><tr><td>ACK</td><td>0×06</td><td>It is sent when a frame has been received and decoded correctly.</td></tr><tr><td>NACK</td><td>0×15</td><td>It is sent when a frame has not been decoded correctly.</td></tr><tr><td>RESET</td><td>0×08</td><t... | <table><tr><td>Command</td><td>Value</td><td>Description</td></tr><tr><td>ACK</td><td>0×06</td><td>It is sent when a frame has been received and decoded correctly.</td></tr></table> | <table><tr><td>NACK</td><td>0×15</td><td>It is sent when a frame has not been decoded correctly.</td></tr><tr><td>RESET</td><td>0×08</td><td>It forces the node to be reset. After this command, the node sends an ACK and resets itself. For the next 2 seconds the node enters a programing mode which allows the central comp... |
f004dd934af35ecfb12802de9b2f588aa0c04d668fb47d61fd9ad800a4cba792.png | simple | <table><tr><td></td><td>N</td><td>%</td><td>% susceptible TMP/SMX</td><td>Ciprofloxacin</td><td>Nitrofurantoin</td></tr><tr><td><i>E. coli</i></td><td>73</td><td>82</td><td>93</td><td>100</td><td>95</td></tr><tr><td><i>P. mirabillis</i></td><td>5</td><td>5.6</td><td>100</td><td>100</td><td>na</td></tr><tr><td><i>K. pne... | <table><tr><td></td><td>N</td><td>%</td><td>% susceptible TMP/SMX</td><td>Ciprofloxacin</td><td>Nitrofurantoin</td></tr><tr><td>E. coli</td><td>73</td><td>82</td><td>93</td><td>100</td><td>95</td></tr><tr><td>P. mirabillis</td><td>5</td><td>5.6</td><td>100</td><td>100</td><td>na</td></tr><tr><td>K. pneumonia</td><td>4<... | <table><tr><td>Total</td><td>89</td><td>100</td></tr></table> |
228a830e40b5d378aff210113a9bb0879ffd29faf1451bf619922c3ee1867680.png | complex | <table><tr><td>Dimension</td><td>Categories</td></tr><tr><td rowspan="3">Primary diagnosis</td><td>Organic mental health problem (most commonly dementia)</td></tr><tr><td>Depression or anxiety</td></tr><tr><td>Other mental health problem e.g., schizophrenia</td></tr><tr><td rowspan="4">Main reason for admission</td><td... | <table><tr><td>Dimension</td><td>Categories</td></tr><tr><td rowspan="3">Primary diagnosis</td><td>Organic mental health problem (most commonly dementia)</td></tr><tr><td>Depression or anxiety</td></tr><tr><td>Other mental health problem e.g., schizophrenia</td></tr><tr><td rowspan="2">Main reason for admission</td><td... | <table><tr><td rowspan="2">Main reason for admission</td><td>Behaviour management related i.e., need for behaviour management, risk of harming others or care breakdown</td></tr><tr><td>Need for diagnostic assessment, medication review or treatment</td></tr><tr><td rowspan="3">Challenging behaviour</td><td>Low (behaviou... |
OCRFlux-pubtabnet-cross
PDF documents are typically paginated, which often results in tables or paragraphs being split across consecutive pages. Accurately detecting and merging such cross-page structures is crucial to avoid generating incomplete or fragmented content.
The merging of two table fragments is especially challenging. For example, the table spanning multiple pages will repeat the header of the first page on the second page. Another difficult scenario is that the table cell contains long content that spans multiple lines within the cell, with the first few lines appearing on the previous page and the remaining lines continuing on the next page. We also observe some cases where tables with a large number of columns are split vertically and placed on two consecutive pages.
OCRFlux-pubtabnet-cross is a benchmark of 9064 samples which can be used to measure the performance of OCR systems in cross-page table merging.
Quick links:
Data Mix
We generate the dataset by splitting each original table in OCRFlux-pubtabnet-single through diverse splitting strategies simulating the real-world scenarios of cross-page table segmentation.
Data Format
Each row in the dataset corresponds to two table fragments and their corresponding ground-truth merged versions, all in HTML format.
Features:
{
'image_name': string, # Name of the original table image
'type': string, # Type of the original table, "simple" or "complex"
'gt_table': string, # Ground-truth HTML of the original table
'table_fragment_1': string, # HTML of the first table fragment
'table_fragment_2': string, # HTML of the second table fragment
}
License
This dataset is licensed under Apache-2.0.
- Downloads last month
- 18